Zevra Therapeutics Inc Stock Price, News & Analysis

Zevra Therapeutics (NasdaqGS: ZVRA) said members of its executive leadership will participate in a fireside discussion at Guggenheim's 2nd Annual Healthcare Innovation Conference in Boston on Wednesday, November 12, 2025 at 11:30 a.m. ET.

Management will also hold one-on-one meetings with registered attendees. A live webcast will be available via the company’s Investor Relations Events & Presentations page at investors.zevra.com.

Zevra Therapeutics (NASDAQ: ZVRA) will report Q3 2025 corporate and financial results on Wednesday, November 5, 2025 after market close. The company will host a conference call and audio webcast the same day at 4:30 p.m. ET.

A webcast link and replay (available for 90 days) are accessible on the Events & Presentations page in the Investor Relations section at investors.zevra.com. Telephone dial-in: US: (800) 579-2543; International: +1 (785) 424-1789. Conference ID: ZVRAQ325. Replay begins at ~5:30 p.m. ET on November 5, 2025.

Zevra Therapeutics (Nasdaq: ZVRA) announced on October 6, 2025 that it granted an aggregate of 38,000 stock options as inducement awards to two new employees under its 2023 Employment Inducement Award Plan.

Each award vests over four years with 25% vesting on the first anniversary of employment and the remainder vesting in three equal annual installments, subject to continued employment. The awards were approved by the Compensation Committee and granted as inducements in accordance with Nasdaq Rule 5635(c)(4). The Inducement Award Plan is reserved for individuals not previously employed by Zevra or returning after a bona fide non‑employment period.

Zevra Therapeutics (NASDAQ:ZVRA) has announced upcoming presentations of clinical data for its two key therapies at major scientific meetings. MIPLYFFA® (arimoclomol), the only treatment shown to halt Niemann-Pick disease type C progression at 12 months, will be featured at the INPDA Meeting in Argentina. The therapy has been administered to over 270 patients, representing the largest NPC clinical trial dataset.

Additionally, data on OLPRUVA® (sodium phenylbutyrate), a novel formulation for treating urea cycle disorders, will be presented. The presentations include an oral session at INPDA and multiple posters at the Child Neurology Society Annual Meeting, covering long-term efficacy, pediatric safety, and administration methods.

Zevra Therapeutics (NASDAQ:ZVRA) presented new positive data for MIPLYFFA® (arimoclomol) in treating Niemann-Pick disease type C (NPC) at the International Congress of Inborn Errors of Metabolism. The company showcased multiple posters highlighting the drug's efficacy and safety profile.

Key findings include: MIPLYFFA's ability to upregulate CLEAR network genes and amplify NPC1 protein levels, reduced disease progression in patients switching from placebo while on miglustat, demonstrated safety in children aged 6 to 24 months, and confirmed effectiveness in real-world settings. The company's poster detailing MIPLYFFA's mechanism of action received a Best Poster Award nomination from ICIEM.

Zevra Therapeutics (NasdaqGS: ZVRA) announced that four posters on MIPLYFFA® (arimoclomol) will be presented at the International Congress of Inborn Errors of Metabolism (ICIEM) in Kyoto, Japan, September 2-6, 2025. MIPLYFFA, approved in the U.S. for treating Niemann-Pick disease type C (NPC), will be featured in presentations including a Best Poster award winner highlighting its mechanism of action.

The presentations will showcase new data from a multi-center pediatric substudy in patients under two years old and a new prespecified efficacy analysis of patients on routine clinical care with miglustat who switched from placebo to MIPLYFFA. The drug has demonstrated long-term clinical outcomes across more than 270 NPC patients worldwide through various clinical trials and programs, representing the most extensive clinical development program in NPC to date.

Zevra Therapeutics (NASDAQ:ZVRA), a commercial-stage rare disease therapy company, has announced its participation in two major investor conferences in September 2025. The company will present at the Cantor Global Healthcare Conference on September 3 at 11:30 a.m. ET and the H.C. Wainwright 27th Annual Global Investment Conference on September 8 at 10:00 a.m. ET.

Management will be available for one-on-one meetings with registered attendees, and live webcasts of the presentations will be accessible through the Investor Relations section of Zevra's website.

Zevra Therapeutics (NASDAQ:ZVRA) reported strong Q2 2025 financial results with net revenue of $25.9 million, primarily driven by MIPLYFFA sales of $21.5 million. The company completed the sale of its Priority Review Voucher for $150.0 million, significantly strengthening its balance sheet.

Key highlights include 129 total MIPLYFFA prescriptions since launch with 52% market access coverage, and the submission of a Marketing Authorisation Application to the European Medicines Agency for arimoclomol in Niemann-Pick Disease Type C. The company reported net income of $74.7 million ($1.24 per basic share) and maintains a strong cash position of $217.7 million.

Zevra Therapeutics (NasdaqGS: ZVRA), a commercial-stage rare disease therapy company, announced its participation in the upcoming Canaccord Genuity 45th Annual Growth Conference. The company's executive team will engage in a fireside chat on August 13, 2025, at 1:00 p.m. ET in Boston, MA.

Management will also be available for one-on-one meetings with registered attendees. Investors can access the live webcast through the "Events & Presentations" section on Zevra's investor relations website at investors.zevra.com.